CDKN2A and neoplasm: Specifically, a clinical study highlighted that reduced somatic copy number of the CDKN2A gene was linked to larger tumors, higher tumor stage, presence of tumor necrosis and microvascular invasion, and could independently predict prognosis (18, 19).